Clinical Trial Update: A Study Investigating the Anti-epileptic Efficacy of Afinitor (Everolimus) in Patients With Refractory Seizures Who Have Focal Cortical Dysplasia Type II (FCD II) [Phase 2]

View source ↗

Summary

Phase 2 trial investigating everolimus for refractory seizures in focal cortical dysplasia type II has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy
• Focal Cortical Dysplasia Type Ii

Drugs mentioned

• Afinitor (everolimus)

Snippet

Sponsor: Yonsei University | Conditions: Epilepsy and Focal Cortical Dysplasia II | Phase 2 | Status: COMPLETED